Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OHR Pharmaceutical Inc    OHRP

OHR PHARMACEUTICAL INC

(OHRP)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
News SummaryMost relevantAll newsOfficial PublicationsSector news

OHR PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Ohr Pharmaceutical, Inc. - OHRP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 05:48pm EDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Ohr Pharmaceutical, Inc. (“Ohr”) (NasdaqCM: OHRP) with NeuBase Therapeutics, Inc. (“NeuBase”) in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ohrp/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OHR PHARMACEUTICAL INC
03/13OHR PHARMACEUTICAL : NeuBase Therapeutics Announces Agreements for $9 Million Fi..
AQ
02/21Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
GL
02/15OHR PHARMACEUTICAL INC : Results of Operations and Financial Condition, Other Ev..
AQ
02/14OHR : Fiscal 1Q Earnings Snapshot
AQ
02/14OHR PHARMACEUTICAL : Management's Discussion and Analysis of Financial Condition..
AQ
02/14Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of ..
GL
02/11OHR PHARMACEUTICAL INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
02/04OHR PHARMACEUTICAL INC : REVERSE SPLIT: 1 of 20
FA
More news
Chart OHR PHARMACEUTICAL INC
Duration : Period :
OHR Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OHR PHARMACEUTICAL INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Managers
NameTitle
Jason Scott Slakter President, Chief Executive Officer & Director
Michael A. Ferguson Chairman
Samuel I. Backenroth CFO, Secretary & Principal Accounting Officer
Glenn L. Stoller Chief Scientific Officer
Orin Zvi Hirschman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OHR PHARMACEUTICAL INC2,543.37%6
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596